COPD Study Leveraging Technegas and AI-Driven Lung Analysis
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Cyclopharm Limited has announced a new clinical research collaboration to evaluate a novel treatment for severe chronic obstructive pulmonary disease (COPD) using Technegas and AI-driven lung analysis. The study, known as the Endoscopic Segmental Sealant Ablation (ESSA) Study, aims to expand treatment options for patients who currently have limited interventional choices. This initiative is part of Cyclopharm's strategy to leverage Technegas beyond its traditional use, addressing significant unmet needs in respiratory medicine.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cyclopharm
- Technegas Recognised in Updated Clinical Guideline
- Insurer Indemnifies Cyclopharm
- Stanford Children's Health to Implement Technegas
- Colombia Approval Marks 67th Country for Technegas
- Cyclopharm Bell Potter Healthcare Conference Presentation
Later from Cyclopharm
- Trading Halt
- CYC Unaudited Trading Update - Preliminary FY2025 Results
- Cyclopharm Successfully Completes A$14 million Placement
- Cyclopharm Capital Raising Investor Presentation
- Technegas Approved at the US National Institutes of Health
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm